CompletedPhase 4NCT04238702
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
Studying Non-genetic systemic disease with glomerulopathy as a major feature
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amsterdam UMC, location VUmc
- Principal Investigator
- Daniel van Raalte, MD PhDAmsterdam UMC, location VU Medical Center
- Intervention
- Empagliflozin 10 MG(drug)
- Enrollment
- 24 target
- Eligibility
- 35-80 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- VU University Medical Center, Amsterdam, North Holland, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04238702 on ClinicalTrials.govOther trials for Non-genetic systemic disease with glomerulopathy as a major feature
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07271186Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney DiseaseRegeneron Pharmaceuticals
- RECRUITINGNANCT06622915Cardiac Performance Evaluation in Children With Steroid Dependent vs Steroid Resistant Nephrotic SyndromeSohag University
- RECRUITINGPHASE3NCT05914155Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic SyndromeShoichi Maruyama MD PhD
See all trials for Non-genetic systemic disease with glomerulopathy as a major feature →